These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

859 related items for PubMed ID: 20885340

  • 21. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H, Bouts AH, Cornelissen EA, Beersma MF, Cransberg K.
    Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
    [Abstract] [Full Text] [Related]

  • 22. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
    Luan FL.
    Transplant Proc; 2013 Sep; 45(1):175-7. PubMed ID: 23267799
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients.
    Jamal AJ, Husain S, Li Y, Famure O, Kim SJ.
    Transplantation; 2014 Mar 15; 97(5):569-75. PubMed ID: 24398852
    [Abstract] [Full Text] [Related]

  • 29. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
    Kuo HT, Huang E, Emami S, Pham PT, Wilkinson AH, Danovitch GM, Bunnapradist S.
    Transplantation; 2012 Mar 15; 93(5):493-502. PubMed ID: 22306574
    [Abstract] [Full Text] [Related]

  • 30. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS.
    Transplantation; 2007 Feb 15; 83(3):290-6. PubMed ID: 17297403
    [Abstract] [Full Text] [Related]

  • 31. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.
    Transpl Infect Dis; 2016 Dec 15; 18(6):904-912. PubMed ID: 27639246
    [Abstract] [Full Text] [Related]

  • 32. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM, Marquez MA, Bazerbachi F, Schiff JR, Cattral MS, McGilvray ID, Norgate A, Selzner M, Rotstein C, Husain S.
    Clin Transplant; 2013 Dec 15; 27(4):503-9. PubMed ID: 23731387
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 15; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.